The mucocutaneous and articular clinical phenotype is the most common presentation of Behçet’s disease (BD).1 Current ...

Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

The FDA has approved Tremfya® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

such as J&J's own Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), and Sun Pharma’s Ilumya (tildrakizumab). FRONTIER 2 included a range of JNJ-2113 doses, with the most effective (100 mg ...

The "Psoriasis in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ResearchAndMarkets.com's offering. This report provides a ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.